Jyong Biotech Ltd. Ordina... (MENS)
NASDAQ: MENS
· Real-Time Price · USD
49.22
-2.78 (-5.35%)
At close: Oct 03, 2025, 2:26 PM
-5.35% (1D)
| Bid | 47.67 |
| Market Cap | 3.74B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.05 |
| PE Ratio (ttm) | -984.4 |
| Forward PE | n/a |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 49.5 |
| Volume | 331,203 |
| Avg. Volume (20D) | 205,555 |
| Open | 51.70 |
| Previous Close | 52.00 |
| Day's Range | 45.70 - 52.50 |
| 52-Week Range | 6.01 - 67.00 |
| Beta | n/a |
| Ex-Dividend Date | n/a |
About MENS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MENS
Website n/a
2 weeks ago
+5.02%
Jyong Biotech shares are trading higher after the ...
Unlock content with
Pro Subscription
2 months ago · seekingalpha.com
Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks RemainJyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large...